

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 785(TM) anti-mouse CD4

RRID:AB_2563053

Type: Antibody

Proper Citation

BioLegend Cat# 100552, RRID:AB_2563053

Antibody Information

URL: http://antibodyregistry.org/AB_2563053

Proper Citation: BioLegend Cat# 100552, RRID:AB_2563053

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_2563053

Vendor: BioLegend

Catalog Number: 100552

Alternative Catalog Numbers: 100551

Record Creation Time: 20250820T011215+0000

Record Last Update: 20250820T101810+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Sawada K, et al. (2026) Ambient temperature regulates CD4+ T cell tonic T cell receptor signaling and responsiveness. iScience, 29(5), 115801.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. Immunity, 59(1), 98.

Maltez VI, et al. (2026) Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment. Immunity, 59(4), 1058.

Lee D, et al. (2026) Interleukin-4-producing type 2 innate lymphoid cells in the lymph node promote proallergic Tfh13 cell differentiation. Immunity, 59(7), 1860.

Kudo-Saito C, et al. (2026) ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer. Cancer research communications, 6(2), 350.

Huang H, et al. (2025) Biomimetic nanoimmunotherapy boosts spatiotemporal PANoptosis and reshapes desmoplastic tumor microenvironment. Cell reports. Medicine, 6(9), 102312.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. Cell reports, 44(7), 115866.

Hao Y, et al. (2025) Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition. Cancer immunology research, 13(2), 185.

Wu Z, et al. (2025) Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell.

Yeat NY, et al. (2025) Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies. Developmental cell, 60(15), 2114.

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. *Immunity*.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8⁺ T cells. *Immunity*, 58(10), 2472.

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. *Cell reports. Medicine*, 6(8), 102251.

Wang S, et al. (2024) Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. *Cell reports. Medicine*, 5(2), 101415.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. *Cancer research communications*, 4(2), 388.

Textor J, et al. (2023) Machine learning analysis of the T cell receptor repertoire identifies sequence features of self-reactivity. *Cell systems*, 14(12), 1059.

Zhao B, et al. (2023) *Helicobacter* spp. are prevalent in wild mice and protect from lethal *Citrobacter rodentium* infection in the absence of adaptive immunity. *Cell reports*, 42(6), 112549.

Pan C, et al. (2023) Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. *Cell metabolism*, 35(12), 2231.

Duan J, et al. (2023) Characterizing CD4 T cell differentiation in mouse small intestine using T cell transfer, lamina propria preparation, and flow cytometry. *STAR protocols*, 4(3), 102485.

McClory SE, et al. (2023) The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR⁺ CD8⁺ effector state, and its deletion improves checkpoint blockade. *Cell reports*, 42(8), 112905.